AJP - Endocrinology and Metabolism, Vol 258, Issue 5 E737-E739, Copyright © 1990 by American Physiological Society
Effects of antimineralocorticoid RU 26752 on steroid-induced hypertension in rats
M. Kalimi, J. Opoku, M. Agarwal and K. Corley
Department of Physiology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
The effect of mineralocorticoid antagonist RU 26752 on the development and
maintenance of hypertension produced by long-term administration of
mineralocorticoid agonist aldosterone has been investigated.
Uninephrectomized, saline-drinking male Sprague-Dawley rats were
subcutaneously implanted with either placebo (control) pellets or pellets
containing 100 micrograms aldosterone, 50 mg RU 26752, or 100 micrograms
aldosterone plus 50 mg RU 26752. Aldosterone treatment resulted in an
increase in blood pressure to 165 +/- 5 mmHg over the control value of 105
+/- 2 mmHg within 3 wk of experimental period. RU 26752 given alone had no
observable hypertensinogenic effect. However, RU 26752 administered with
aldosterone significantly prevented the hypertension produced by
aldosterone alone. RU 26752 when given with aldosterone was able to prevent
the aldosterone-induced increase in saline consumption, increase urine
output, and reduce urinary Na+ excretion. The results presented suggest
that long-term administration of antimineralocorticoid RU 26752 in vivo to
Sprague-Dawley rats prevents the aldosterone-induced hypertension.
